Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,464 total articles

SEALSQ’s Sister Company, WISeSat.Space, Completes Business Combination with Columbus Acquisition Corporation

SEALSQ’s Sister Company, WISeSat.Space, Completes Business Combination with Columbus Acquisition Corporation

WISeSat.Space Holdings Corp., a space technology company focused on secure satellite communications for IoT applications, completed its business combination with Columbus Acquisition Corporation and commenced trading on Nasdaq under the ticker SAIQ. As a subsidiary of WISeQey Corp., WISeSat.Space aims to expand satellite infrastructure integrating …

Pasqal Appoints Roger L. Chuchen as Head of Investor Relations

Pasqal Appoints Roger L. Chuchen as Head of Investor Relations

Pasqal, a Nasdaq-listed quantum computing firm, appointed Roger L. Chuchen as Head of Investor Relations to strengthen communication with investors and analysts as the company scales its commercial operations and expands its global customer base. Chuchen brings over 25 years of technology and investment experience, aiming to articulate Pasqal's lon…

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus

Biogen Inc. announced encouraging 52-week Phase 2 data from its ongoing AMETHYST Phase 2/3 study of litifilimab, an investigational therapy for cutaneous lupus erythematosus (CLE). Results show continued and rapid improvement in skin symptoms, with over 27% of patients achieving clear or almost clear skin, and a consistent safety profile. The FDA g…

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

CRISPR Therapeutics announced it will present Phase 1 clinical data of zugocabtagene geleucel (zugo-cel), a CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy targeting CD19 for autoimmune diseases, at the American College of Rheumatology Convergence 2026. The therapy is under evaluation across rheumatologic, hematologic, and neurologic autoimmu…

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug

Climb Bio, a clinical-stage biotechnology company, will present new clinical data for its investigational drugs CLYM116 and budoprutug targeting immune-mediated kidney diseases at the American Society of Nephrology Kidney Week 2026. The data includes preliminary Phase 1 results for CLYM116 in healthy volunteers and Phase 2 data for budoprutug in pr…

newcleo plc Reports First Half 2026 Financial and Operational Results

newcleo plc Reports First Half 2026 Financial and Operational Results

newcleo plc announced its first-half 2026 financial and operational results following its business combination and Nasdaq listing under ticker NWCL. The company raised approximately $247 million through the SPAC merger and PIPE financing, plus additional funds, totaling over $1 billion raised since inception. Key operational advances include major …

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

Vera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026

Vera Therapeutics announced that the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA (atacicept-vymj) in treating IgA nephropathy will be highlighted in a late-breaking oral presentation at ASN Kidney Week 2026. Additional interim data from the Phase 2 PIONEER trial in glomerular diseases will also be presented. TRUTAKNA is the first app…

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

Artiva Biotherapeutics announced multiple data presentations at the American College of Rheumatology (ACR) Convergence 2026, featuring updated clinical results on its AlloNK® cell therapy combined with rituximab for treating refractory rheumatoid arthritis and other autoimmune diseases. The company also plans to initiate a Phase 3 registrational tr…

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

ProKidney Corp., a clinical-stage biotechnology company focused on chronic kidney disease (CKD), announced it will present eight abstracts at the American Society of Nephrology's Kidney Week 2026. The presentations highlight translational and clinical data supporting the multifactorial mechanism of their lead cell therapy candidate, rilparencel, wh…

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

Candel Therapeutics announced it will present promising clinical and mechanistic data from its lead immunotherapy candidates, aglatimagene besadenovec and linoserpaturev, at the SITC 41st Annual Meeting. The presentations highlight immune activation and improved survival in patients with progressive non-small cell lung cancer (NSCLC) despite prior …

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026

MiNK Therapeutics announced new data presentations on their allogeneic invariant natural killer T (iNKT) cell therapies, including agenT-797 and MiNK-215, showing potential efficacy against checkpoint inhibitor-resistant colorectal cancer liver metastases and senescent tumor cells and fibroblasts. The data support ongoing clinical trials and highli…